EMERGE BIOSCIENCES PTE LTD. – Trademark Portfolio
Entity Type: 24
EMERGE BIOSCIENCES PTE LTD. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 2 are pending. Notable registered marks include XENLETA, YUSIMRY, and NABRIVA THERAPEUTICS. The owner is based in SINGAPORE.
133 CECIL STREET
#17-03, KECK SENG TOWER
SINGAPORE 069535 , SG
Showing of trademarks Trademarks
Trademark Classifications
EMERGE BIOSCIENCES PTE LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does EMERGE BIOSCIENCES PTE LTD. have?
EMERGE BIOSCIENCES PTE LTD. has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 pending.
What trademark classes does EMERGE BIOSCIENCES PTE LTD. file in?
EMERGE BIOSCIENCES PTE LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are EMERGE BIOSCIENCES PTE LTD.'s most well-known trademarks?
EMERGE BIOSCIENCES PTE LTD.'s registered trademark portfolio includes well-known marks such as XENLETA, YUSIMRY, and NABRIVA THERAPEUTICS. These are among 4 currently registered trademarks in the portfolio.
What is EMERGE BIOSCIENCES PTE LTD.'s trademark registration success rate?
EMERGE BIOSCIENCES PTE LTD. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 2 applications are pending review.